Karen B. Addison

Array ( [id] => 19020536 [patent_doc_number] => 20240076707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => METHOD FOR MODIFYING DNA BY UTILIZING GLYCOSYLASE AND OXYAMINE COMPOUND [patent_app_type] => utility [patent_app_number] => 18/273552 [patent_app_country] => US [patent_app_date] => 2021-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273552 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18583175 [patent_doc_number] => 20230265435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => COMPOSITION COMPRISING OSTEOPONTIN INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF NEURODEGENERATIVE DISEASE [patent_app_type] => utility [patent_app_number] => 18/000501 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7443 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18147574 [patent_doc_number] => 20230021431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => OLIGONUCLEOTIDES FOR SARS-CoV-2 MODULATION [patent_app_type] => utility [patent_app_number] => 17/333839 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17333839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18485248 [patent_doc_number] => 20230212581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => COMPOSITIONS AND METHODS OF INDUCING RNAI OR TYPE I IFN COMPETENT CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/927840 [patent_app_country] => US [patent_app_date] => 2021-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18469207 [patent_doc_number] => 20230203491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR TREATING COVID-19 CONTAINING SAME [patent_app_type] => utility [patent_app_number] => 17/999399 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420527 [patent_doc_number] => 20230174989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => Methods and Compositions for the ADAR-Mediated Editing of ABCA4 [patent_app_type] => utility [patent_app_number] => 17/924063 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -143 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065799 [patent_doc_number] => 20210268014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => MICRORNA 19A/19B FOR USE IN TREATING A PATHOLOGICAL CONDITION ASSOCIATED WITH BONE LOSS OR REDUCED MUSCLE FUNCTION [patent_app_type] => utility [patent_app_number] => 17/320649 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19700057 [patent_doc_number] => 12194056 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => CCR7 aptamers and uses thereof [patent_app_type] => utility [patent_app_number] => 17/319391 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 4482 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17319391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511648 [patent_doc_number] => 20230227824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3 [patent_app_type] => utility [patent_app_number] => 17/998463 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20106953 [patent_doc_number] => 12357651 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Systems and methods for use of adenosine triphosphate (ATP) to relieve symptoms of COVID-19 and related infections [patent_app_type] => utility [patent_app_number] => 17/314962 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 1308 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436414 [patent_doc_number] => 20230183708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => PD-1-specific antisense oligonucleotide and its use in therapy [patent_app_type] => utility [patent_app_number] => 17/919611 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214830 [patent_doc_number] => 20210348167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/245682 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460680 [patent_doc_number] => 20220073985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => DISEASE STRATIFICATION OF LIVER DISEASE AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 17/239461 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376286 [patent_doc_number] => 20230151369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING TDP-43 AND FUS AGGREGATION [patent_app_type] => utility [patent_app_number] => 17/919459 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537815 [patent_doc_number] => 20230242916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => METHOD AND DRUG FOR TREATING HURLER SYNDROME [patent_app_type] => utility [patent_app_number] => 17/918877 [patent_app_country] => US [patent_app_date] => 2021-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007442 [patent_doc_number] => 20210238603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => BETA CATENIN NUCLEIC ACID INHIBITOR MOLECULE [patent_app_type] => utility [patent_app_number] => 17/231696 [patent_app_country] => US [patent_app_date] => 2021-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17231696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19503832 [patent_doc_number] => 12115230 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => Base editing of ANGPTL3 and methods of using same for treatment of disease [patent_app_type] => utility [patent_app_number] => 17/918092 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 84 [patent_figures_cnt] => 76 [patent_no_of_words] => 185281 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156406 [patent_doc_number] => 20210317457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES [patent_app_type] => utility [patent_app_number] => 17/226710 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17226710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036555 [patent_doc_number] => 20220380770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES [patent_app_type] => utility [patent_app_number] => 17/226686 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17226686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17141994 [patent_doc_number] => 20210310006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/224179 [patent_app_country] => US [patent_app_date] => 2021-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224179 [rel_patent_id] =>[rel_patent_doc_number] =>)